Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells

Markus D. Sachs, Meera Ramamurthy, Henk Van Der Poel, Thomas J. Wickham, Martine Lamfers, Winald Gerritsen, Wasim Chowdhury, Ying Li, Mark P. Schoenberg, Ronald Rodriguez

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Studies on bladder cancer cell lines have shown that low adenoviral (Ad) infectivity is associated with low-level coxsackie adenovirus receptor (CAR) expression. Recently, we and others demonstrated a tumor stage- and grade-dependent downregulation of CAR expression in a large series of clinical bladder cancer specimens. Here, we demonstrate adenoviral gene transfer can be markedly enhanced in bladder cancer cells by upregulation of CAR through the use of certain differentiating agents, including the histone deacetylase inhibitors (HDACI) trichostatin A and sodium phenylbutyrate. CAR upregulation to supraphysiologic levels was demonstrated by quantitative rt-PCR, Western blotting, flow cytometry and adenoviral gene transfer. Normal urothelial cells and CAR-positive papilloma cells (RT4) failed to demonstrate upregulation under the same conditions. Upregulation was cell cycle dependent, associated with increased adenoviral gene transfer and persisted for at least 7 days after a single treatment. Such upregulation, however, appears to be tumor cell specific, as other CAR-negative cell lines failed to demonstrate enhanced adenoviral gene transfer with the same treatments. These results provide a rational basis for combining HDACI therapy with gene therapy as a method of augmenting activity in bladder cancer, but this strategy may not be universally applicable to other cell types.

Original languageEnglish (US)
Pages (from-to)477-486
Number of pages10
JournalCancer Gene Therapy
Volume11
Issue number7
DOIs
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Coxsackie and Adenovirus Receptor-Like Membrane Protein
Histone Deacetylase Inhibitors
Urinary Bladder Neoplasms
Up-Regulation
Genes
trichostatin A
Cell Line
Papilloma
Genetic Therapy
Neoplasms
Cell Cycle
Flow Cytometry
Therapeutics
Down-Regulation
Western Blotting
Polymerase Chain Reaction

Keywords

  • Adenoviral gene therapy
  • Bladder cancer
  • Coxsackie adenovirus receptor
  • Receptor upregulation

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Sachs, M. D., Ramamurthy, M., Van Der Poel, H., Wickham, T. J., Lamfers, M., Gerritsen, W., ... Rodriguez, R. (2004). Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Therapy, 11(7), 477-486. https://doi.org/10.1038/sj.cgt.7700726

Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. / Sachs, Markus D.; Ramamurthy, Meera; Van Der Poel, Henk; Wickham, Thomas J.; Lamfers, Martine; Gerritsen, Winald; Chowdhury, Wasim; Li, Ying; Schoenberg, Mark P.; Rodriguez, Ronald.

In: Cancer Gene Therapy, Vol. 11, No. 7, 07.2004, p. 477-486.

Research output: Contribution to journalArticle

Sachs, MD, Ramamurthy, M, Van Der Poel, H, Wickham, TJ, Lamfers, M, Gerritsen, W, Chowdhury, W, Li, Y, Schoenberg, MP & Rodriguez, R 2004, 'Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells', Cancer Gene Therapy, vol. 11, no. 7, pp. 477-486. https://doi.org/10.1038/sj.cgt.7700726
Sachs, Markus D. ; Ramamurthy, Meera ; Van Der Poel, Henk ; Wickham, Thomas J. ; Lamfers, Martine ; Gerritsen, Winald ; Chowdhury, Wasim ; Li, Ying ; Schoenberg, Mark P. ; Rodriguez, Ronald. / Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. In: Cancer Gene Therapy. 2004 ; Vol. 11, No. 7. pp. 477-486.
@article{b357b14c1afd4c16aeb9c51c99a5aa73,
title = "Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells",
abstract = "Studies on bladder cancer cell lines have shown that low adenoviral (Ad) infectivity is associated with low-level coxsackie adenovirus receptor (CAR) expression. Recently, we and others demonstrated a tumor stage- and grade-dependent downregulation of CAR expression in a large series of clinical bladder cancer specimens. Here, we demonstrate adenoviral gene transfer can be markedly enhanced in bladder cancer cells by upregulation of CAR through the use of certain differentiating agents, including the histone deacetylase inhibitors (HDACI) trichostatin A and sodium phenylbutyrate. CAR upregulation to supraphysiologic levels was demonstrated by quantitative rt-PCR, Western blotting, flow cytometry and adenoviral gene transfer. Normal urothelial cells and CAR-positive papilloma cells (RT4) failed to demonstrate upregulation under the same conditions. Upregulation was cell cycle dependent, associated with increased adenoviral gene transfer and persisted for at least 7 days after a single treatment. Such upregulation, however, appears to be tumor cell specific, as other CAR-negative cell lines failed to demonstrate enhanced adenoviral gene transfer with the same treatments. These results provide a rational basis for combining HDACI therapy with gene therapy as a method of augmenting activity in bladder cancer, but this strategy may not be universally applicable to other cell types.",
keywords = "Adenoviral gene therapy, Bladder cancer, Coxsackie adenovirus receptor, Receptor upregulation",
author = "Sachs, {Markus D.} and Meera Ramamurthy and {Van Der Poel}, Henk and Wickham, {Thomas J.} and Martine Lamfers and Winald Gerritsen and Wasim Chowdhury and Ying Li and Schoenberg, {Mark P.} and Ronald Rodriguez",
year = "2004",
month = "7",
doi = "10.1038/sj.cgt.7700726",
language = "English (US)",
volume = "11",
pages = "477--486",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells

AU - Sachs, Markus D.

AU - Ramamurthy, Meera

AU - Van Der Poel, Henk

AU - Wickham, Thomas J.

AU - Lamfers, Martine

AU - Gerritsen, Winald

AU - Chowdhury, Wasim

AU - Li, Ying

AU - Schoenberg, Mark P.

AU - Rodriguez, Ronald

PY - 2004/7

Y1 - 2004/7

N2 - Studies on bladder cancer cell lines have shown that low adenoviral (Ad) infectivity is associated with low-level coxsackie adenovirus receptor (CAR) expression. Recently, we and others demonstrated a tumor stage- and grade-dependent downregulation of CAR expression in a large series of clinical bladder cancer specimens. Here, we demonstrate adenoviral gene transfer can be markedly enhanced in bladder cancer cells by upregulation of CAR through the use of certain differentiating agents, including the histone deacetylase inhibitors (HDACI) trichostatin A and sodium phenylbutyrate. CAR upregulation to supraphysiologic levels was demonstrated by quantitative rt-PCR, Western blotting, flow cytometry and adenoviral gene transfer. Normal urothelial cells and CAR-positive papilloma cells (RT4) failed to demonstrate upregulation under the same conditions. Upregulation was cell cycle dependent, associated with increased adenoviral gene transfer and persisted for at least 7 days after a single treatment. Such upregulation, however, appears to be tumor cell specific, as other CAR-negative cell lines failed to demonstrate enhanced adenoviral gene transfer with the same treatments. These results provide a rational basis for combining HDACI therapy with gene therapy as a method of augmenting activity in bladder cancer, but this strategy may not be universally applicable to other cell types.

AB - Studies on bladder cancer cell lines have shown that low adenoviral (Ad) infectivity is associated with low-level coxsackie adenovirus receptor (CAR) expression. Recently, we and others demonstrated a tumor stage- and grade-dependent downregulation of CAR expression in a large series of clinical bladder cancer specimens. Here, we demonstrate adenoviral gene transfer can be markedly enhanced in bladder cancer cells by upregulation of CAR through the use of certain differentiating agents, including the histone deacetylase inhibitors (HDACI) trichostatin A and sodium phenylbutyrate. CAR upregulation to supraphysiologic levels was demonstrated by quantitative rt-PCR, Western blotting, flow cytometry and adenoviral gene transfer. Normal urothelial cells and CAR-positive papilloma cells (RT4) failed to demonstrate upregulation under the same conditions. Upregulation was cell cycle dependent, associated with increased adenoviral gene transfer and persisted for at least 7 days after a single treatment. Such upregulation, however, appears to be tumor cell specific, as other CAR-negative cell lines failed to demonstrate enhanced adenoviral gene transfer with the same treatments. These results provide a rational basis for combining HDACI therapy with gene therapy as a method of augmenting activity in bladder cancer, but this strategy may not be universally applicable to other cell types.

KW - Adenoviral gene therapy

KW - Bladder cancer

KW - Coxsackie adenovirus receptor

KW - Receptor upregulation

UR - http://www.scopus.com/inward/record.url?scp=3142580300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142580300&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700726

DO - 10.1038/sj.cgt.7700726

M3 - Article

VL - 11

SP - 477

EP - 486

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 7

ER -